CEROCERO THERAPEUTICS HOLDINGS, INC.vs its industry peers
A metric-by-metric comparison of CERO THERAPEUTICS HOLDINGS, INC. against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CEROEsta | $7M#8 | — | — | — | — | — | — | — | — | — | -98.7%#16 | 1.8%#3 |
| INTS | $13M#1 | — | 1.5x#8 | — | — | 28.7%#4 | — | -126.0%#5 | — | — | -40.5%#4 | — |
| BCLI | $13M#2 | — | — | — | — | 11.3%#6 | — | — | — | — | -1.7%#3 | — |
| ENGNW | $12M#3 | 0.1x#3 | 0.0x#1 | — | — | -112.7%#13 | — | -46.0%#1 | — | — | -72.8%#9 | — |
| SNTI | $12M#4 | — | — | 535.5x#6 | — | -16.4%#10 | -312631.8%#8 | — | — | — | -73.2%#10 | — |
| INAB | $11M#5 | — | 0.6x#3 | — | — | 36.1%#3 | — | -105.9%#4 | — | — | -50.0%#6 | — |
| AIM | $7M#6 | — | 0.9x#6 | 82.6x#5 | -48.2%#4 | 19.4%#5 | -13254.5%#4 | -180.2%#7 | -7934.7%#6 | — | -90.5%#12 | — |
| CELZ | $7M#7 | — | 0.8x#5 | 1208.6x#7 | -45.5%#3 | -9.1%#8 | -102380.2%#7 | -69.3%#3 | -66.1%#2 | 3#1 | -65.5%#8 | — |
| PMCB | $5M#9 | — | 0.2x#2 | — | — | -163.4%#14 | — | -58.3%#2 | -40.0%#1 | — | -48.7%#5 | — |
| BKHAR | $5M#10 | — | — | — | — | -30.6%#11 | — | — | — | — | 605.8%#1 | 967.0%#1 |
| ZIVO | $5M#11 | — | — | 31.3x#3 | 468.6%#1 | -72.1%#12 | -8498.9%#2 | — | — | — | 0.0%#2 | — |
| LIMNW | $4M#12 | — | 12.5x#9 | — | — | -187.8%#15 | — | -3395.2%#9 | -170.3%#4 | — | -65.3%#7 | — |
| CLDI | $3M#13 | 0.0x#1 | 1.1x#7 | 77.2x#4 | — | 10.1%#7 | -44977.8%#6 | -635.4%#8 | — | — | -95.0%#14 | — |
| BCAB | — | 0.1x#2 | — | — | — | -14.6%#9 | -19768.3%#5 | — | — | — | -92.0%#13 | — |
| CRIS | $3M#15 | 0.1x#4 | 0.6x#4 | 0.3x#1 | -13.4%#2 | 82.5%#2 | -60.5%#1 | -161.5%#6 | -87.3%#3 | — | -95.8%#15 | — |
| WINT | $3M#14 | — | — | 17.1x#2 | -88.9%#5 | 91.2%#1 | -13201.5%#3 | — | -308.7%#5 | — | -75.1%#11 | 19.4%#2 |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-02.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice